{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:27:16Z","timestamp":1777663636202,"version":"3.51.4"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.expneurol.2004.03.022","type":"journal-article","created":{"date-parts":[[2004,5,8]],"date-time":"2004-05-08T07:19:35Z","timestamp":1084000775000},"page":"128-138","source":"Crossref","is-referenced-by-count":41,"title":["Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate"],"prefix":"10.1016","volume":"188","author":[{"given":"M.A.","family":"Silverdale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Millan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2004.03.022_BIB1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1073\/pnas.93.5.1945","article-title":"A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice","volume":"93","author":"Accili","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/01.WNL.0000052681.28286.52","article-title":"Initial agonist treatment of Parkinson disease: a critique","volume":"60","author":"Albin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB3","first-page":"187","article-title":"A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194","volume":"287","author":"Audinot","year":"1998","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.870060404","article-title":"Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate","volume":"6","author":"Aziz","year":"1991","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2402638","article-title":"Reversal of experimental parkinsonism by lesions of the subthalamic nucleus","volume":"249","author":"Bergman","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB7","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1523\/JNEUROSCI.17-17-06761.1997","article-title":"Dopaminergic neurons intrinsic to the primate striatum","volume":"17","author":"Betarbet","year":"1997","journal-title":"J. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1096\/fj.00-0637fje","article-title":"Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease","volume":"15","author":"Bezard","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat. Med"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB10","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB11","first-page":"794","article-title":"Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys","volume":"283","author":"Blanchet","year":"1997","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB13","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","article-title":"Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa","volume":"94","author":"Bordet","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1046\/j.1460-9568.2000.00089.x","article-title":"Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats","volume":"12","author":"Bordet","year":"2000","journal-title":"Eur. J. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0028-3908(98)00213-5","article-title":"Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice","volume":"38","author":"Boulay","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0006-8993(91)91456-B","article-title":"Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA","volume":"564","author":"Bouthenet","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB17","first-page":"200","article-title":"Actions of the novel naphtoxazine D3\/D2 receptor agonist, S32504, in models predictive of antiparkinsonian properties","volume":"27","author":"Brocco","year":"2001","journal-title":"Abstr.-Soc. Neurosci"},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2004.03.022_BIB18","first-page":"40","article-title":"Quantitative assessment of dyskinesias in subhuman primates","volume":"14","author":"Brotchie","year":"1999","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0006-8993(95)00229-J","article-title":"Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex","volume":"680","author":"Calon","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB20","first-page":"51","article-title":"Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors","volume":"45","author":"Chio","year":"1994","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s002130050567","article-title":"Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach","volume":"136","author":"Clifford","year":"1998","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB22","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","article-title":"Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 long, D3 and D4.4 receptors expressed in Chinese hamster ovary cells","volume":"127","author":"Coldwell","year":"1999","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1124\/mol.56.5.1025","article-title":"Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism","volume":"56","author":"Cussac","year":"1999","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB24","first-page":"1292","article-title":"The novel dopamine receptor partial agonist, BP897, is a potent ligand at diverse adrenergic and serotonergic receptors","volume":"26","author":"Cussac","year":"2000","journal-title":"Abstr.-Am. Soc. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s002100000217","article-title":"[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors","volume":"361","author":"Cussac","year":"2000","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(00)00149-7","article-title":"The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors","volume":"394","author":"Cussac","year":"2000","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0028-3908(93)90177-5","article-title":"Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other \u201cD-2-like\u201d agonists","volume":"32","author":"Daly","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB28","first-page":"77","article-title":"Sumanirole (Pharmacia)","volume":"4","author":"de Paulis","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0960-894X(99)00312-1","article-title":"Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist","volume":"9","author":"Dubuffet","year":"1999","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/PL00005263","article-title":"Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding","volume":"358","author":"Ekman","year":"1998","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","article-title":"Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan","volume":"16","author":"Fox","year":"2001","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB32","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1997.68010001.x","article-title":"Two intracellular pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP","volume":"68","author":"Griffon","year":"1997","journal-title":"J. Neurochem"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","article-title":"Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys","volume":"361","author":"Grondin","year":"2000","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB35","first-page":"1598","article-title":"Behavioural effects of selective dopamine D3 receptor agonists\/antagonist in primate model of Parkinson's disease","volume":"25","author":"Hadj Tahar","year":"1999","journal-title":"Abstr.-Soc. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s002130050131","article-title":"Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907","volume":"128","author":"Hall","year":"1996","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB37","first-page":"53","article-title":"Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of l-dopa-induced dyskinesia","volume":"78","author":"Henry","year":"1998","journal-title":"Adv. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1998.6996","article-title":"Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat","volume":"155","author":"Henry","year":"1999","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","article-title":"The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-dopa in the MPTP-lesioned primate model of Parkinson's disease","volume":"14","author":"Henry","year":"1999","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the mptp-lesioned primate model of Parkinson's disease","volume":"171","author":"Henry","year":"2001","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0006-8993(94)91121-5","article-title":"Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin","volume":"648","author":"Herroelen","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0006-8993(95)01309-1","article-title":"Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and l-DOPA treatment","volume":"709","author":"Hurley","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0304-3940(96)12884-6","article-title":"D3 receptor expression within the basal ganglia is not affected by Parkinson's disease","volume":"214","author":"Hurley","year":"1996","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(01)00139-5","article-title":"Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs","volume":"90","author":"Joyce","year":"2001","journal-title":"Pharmacol. Ther"},{"issue":"Suppl. 5","key":"10.1016\/j.expneurol.2004.03.022_BIB45","first-page":"10","article-title":"D3 receptors contribute to the neuroprotective properties of D3\/D2 agonists against MPP-induced neurotoxicity but not DA-induced toxicity in SH-SY5Y cells","volume":"17","author":"Joyce","year":"2002","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0006-8993(02)03396-6","article-title":"Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors","volume":"955","author":"Joyce","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02246265","article-title":"Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning","volume":"122","author":"Khroyan","year":"1995","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0169-328X(93)90188-U","article-title":"Dopamine D3 receptor mRNA and binding sites in human brain","volume":"18","author":"Landwehrmeyer","year":"1993","journal-title":"Brain Res. Mol. Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB50","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1073\/pnas.89.17.8155","article-title":"Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin","volume":"89","author":"Levesque","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB51","first-page":"202","article-title":"Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures","volume":"289","author":"Ling","year":"1999","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB52","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","article-title":"Antiparkinsonian activity and dyskinesia risk of ropinirole and l-DOPA combination therapy in drug na\u0131\u0308ve MPTP-lesioned common marmosets (Callithrix jacchus)","volume":"16","author":"Maratos","year":"2000","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/exnr.2002.8055","article-title":"Both short- and long-acting D-1\/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)","volume":"179","author":"Maratos","year":"2003","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB54","article-title":"Paradoxical effects of dopamine D3 receptor antagonist U99194A on locomotor activity and dopamine synthesis","volume":"27","author":"Mattingly","year":"2001","journal-title":"Abstr.-Soc. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB55","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB56","first-page":"1063","article-title":"S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626","volume":"293","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB57","first-page":"1048","article-title":"S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626","volume":"293","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB58","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/S0924-977X(02)80491-6","article-title":"Antipsychotic profile of the novel benzopyranopyrrole and preferential dopamine D3 receptor antagonist, S33138","volume":"12","author":"Millan","year":"2002","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB59","unstructured":"Millan, M.J., Seguin, L., Gobert, A., Cussac, D., Brocco, M., in pressa. The role of dopamine D3 as compared to D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology."},{"key":"10.1016\/j.expneurol.2004.03.022_BIB89","unstructured":"Millan, M.J., DiCara, B., Hill, M., Jackson, M., Joyce, J., Brotchie, J., McGuire, S., Crossman, A., Jenner, P., Gobert, A., Peglion, J-L., Broco, M. in pressb. S32504, a novel naphtoxazine agonist at dopamine D3\/D2 receptors II: actions in rodent, primate and cellular models of anti-parkinsonian activity in comparisons to ropinirole. J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.expneurol.2004.03.022_BIB60","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1046\/j.1460-9568.1998.00264.x","article-title":"Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies","volume":"10","author":"Morissette","year":"1998","journal-title":"Eur. J. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB61","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1073\/pnas.91.23.11271","article-title":"Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain","volume":"91","author":"Murray","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"165","author":"Nash","year":"2000","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB63","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ana.10189","article-title":"Evolution of the response to levodopa during the first 4 years of therapy","volume":"51","author":"Nutt","year":"2002","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0006-8993(98)01049-X","article-title":"Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration","volume":"813","author":"Oh","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian model","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB66","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB67","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002130050861","article-title":"Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated l-dopa-primed common marmosets","volume":"142","author":"Pearce","year":"1999","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0014-2999(98)00896-6","article-title":"Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors","volume":"366","author":"Perachon","year":"1999","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(96)00695-4","article-title":"Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype","volume":"317","author":"Piercey","year":"1996","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0306-4522(00)00130-5","article-title":"Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment","volume":"98","author":"Quik","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB74","first-page":"33","article-title":"Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?","volume":"55","author":"Rascol","year":"1999","journal-title":"J. Neural Transm., Suppl"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB75","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB76","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"Rascol","year":"2001","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2003.09.001","article-title":"Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia","volume":"185","author":"Ravenscroft","year":"2004","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB77","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1046\/j.1460-9568.1998.00173.x","article-title":"Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions","volume":"10","author":"Ridray","year":"1998","journal-title":"Eur. J. Neurosci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB78","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1124\/mol.52.3.508","article-title":"Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor","volume":"52","author":"Robinson","year":"1997","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB79","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.870130506","article-title":"Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease","volume":"13","author":"Ryoo","year":"1998","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB80","first-page":"1239","article-title":"Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents","volume":"275","author":"Sautel","year":"1995","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB81","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","article-title":"Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"18","author":"Savola","year":"2003","journal-title":"Mov. Disord"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB82","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0165-6147(94)90323-9","article-title":"Dopamine receptor pharmacology","volume":"15","author":"Seeman","year":"1994","journal-title":"Trends Pharmacol. Sci"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050479","article-title":"The D3 dopamine receptor in cellular and organismal function","volume":"135","author":"Shafer","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0006-8993(97)01078-0","article-title":"D3 dopamine receptor mRNA is widely expressed in the human brain","volume":"779","author":"Suzuki","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB86","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0306-4522(02)00535-3","article-title":"Alterations in striatal neuropeptide mRNA produced by repeated administration of l-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets","volume":"115","author":"Tel","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB87","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0306-4522(02)00548-1","article-title":"Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitisation to levodopa","volume":"116","author":"Van Kampen","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2004.03.022_BIB88","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0278-5846(01)00152-X","article-title":"The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion (\u2018knockout\u2019)","volume":"25","author":"Waddington","year":"2001","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488604001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488604001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T17:26:18Z","timestamp":1549733178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488604001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0014488604001281"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2004.03.022","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}